New York City
Local Staff Contacts
New York, NY 10006
Research Grant Program
Research Grant Program
The Leukemia & Lymphoma Society Research Grant Program provides grant funding to support research at academic centers around the world, through three grant mechanisms, outlined below.
Translational Research Program - Turning Science into Therapy
TRP Grants are $600,000 over three years
The Translational Research Program (TRP) funds outstanding investigations deemed by our expert advisors most likely to translate basic biomedical discoveries into new, safe, and effective treatments, ultimately prolonging and enhancing patients' lives. The first of its kind, the TRP was created in 1995, in consultation wtih the National Cancer Institute, which favorably reviews successful TRP projects for federal funding of subsequent clinical research.
Specialized Center of Research Program - Promoting Critical Teamwork
SCOR grants are $1.25 million annually for five years, totalling $6.25 million
The Specialized Center of Research Program (SCOR) is an ambitious research program, established in 2000 to support the collaborative research necessary to most efficiently develop new treatments and cures. A SCOR team is composed of at least three independent research programs that are integrated and supported by scientific core laboratories. The program was established to encourage multidisciplinary research focused on the prevention or cure of leukemia, lymphoma or myeloma.
Career Development Program - Investigating in and Vesting Specialized Researchers
CDP grants range from $165,000 over three years to $550,000 over five years
LLS's Career Development Program (CDP) supports fundamental research in genetics, molecular and cell biology, molecular pharmacology, molecular virology, and immunology. The program recruits and supports young scientists in blood cancer research helping to populate the field with the best and brightest young researchers who are accomplishing cutting-edge research in established and new laboratories. CDP funds talented investigators at different points in their developing careers: Fellows, Special Fellows, and Special Fellows in Clinical Research during their post-doctoral training years, and Scholars and Scholars in Clinical Research early in their first independent academic positions.
Fellows - Can receive $55,000 per year for three years
He or she must be a promising investigator with less than two years of postdoctoral research training. This award encourages researchers to embark on an academic career involving clinical or fundamental research in, or related to, leukemia, lymphoma or myeloma under a research sponsor's direction.
Special Fellow - Awarded $65,000 per year for three years
He or she must be a qualified investigator who has completed a minimum of two years of postdoctoral research training and is continuing the research under a sponsor's direction. This award is meant to permit the resaercher to begin to transition to an independent research program. A Special Fellow in Clinical Research can receive a grant at the same funding level but the researcher must hold a Ph.D., M.D., or equivalent degree and has completed at least two years of clinical hematology, oncology, hematology/oncology, or hematopathology training or postdoctoral research training in a clinical discipline (such as cytogenetics or molecular pathology). The researcher needs to show evidence that his/her career focus will be on preventing, diagnosing, or treating leukemia, lymphoma or myeloma.
Scholars - Receive $110,000 per year for five years
The scholar must be a highly qualified investigator who has shown a capacity for independent, sustained original investigation in the field of leukemia, lymphoma and myeloma. He or she should hold an independent faculty-level or equivalent position and have obtained substantial support for their research from a national agency.
Scholars in Clinical Research - Receive $110,000 per year for five years
The researcher must be a highly qualified investigator who holds an independent faculty-level appointment and is conducting original, independent applied research, often involving early-stage clinical trials that will advance the prevention, diagnosis or treatment of hematologic malignancies. He or she is expected to have concomitant support for their research from another source or agency.